Skip to main content
Erschienen in:

01.11.2024 | Osteoporose | FB_CME

Aspekte bei der Behandlung älterer Patientinnen und Patienten

Die aktuelle Leitlinie für Osteoporose

verfasst von: Univ. Prof. Dr. med. Michael Drey, Univ. Prof. Dr. Dr. Sven Otto, Dr. Friederike Thomasius, Prof. Dr. med. Ralf Schmidmaier

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 3/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Fünf Jahre nach dem letzten Update wurde die S3-Leitline zur Diagnostik, Prophylaxe und Therapie der Osteoporose einer substanziellen Überarbeitung unterzogen. Nicht nur die Zulassung der osteoanabolen Substanz Romosozumab, sondern eine Vielzahl an Publikationen im Bereich der Risikofaktoren und der spezifischen Therapie der Osteoporose seit der letzten Aktualisierung führten zu wichtigen neuen Empfehlungen, die in diesem Artikel zusammengefasst sind.
Literatur
1.
Zurück zum Zitat Cummings SR et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its Extension. J Bone Miner Res. 2018;33:190-8 Cummings SR et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its Extension. J Bone Miner Res. 2018;33:190-8
2.
Zurück zum Zitat Dautzenberg L et al. Interventions for preventing falls and fall-related fractures in community-dwelling older adults: A systematic review and network meta-analysis. J Am Geriatr Soc. 2021;69:2973-84 Dautzenberg L et al. Interventions for preventing falls and fall-related fractures in community-dwelling older adults: A systematic review and network meta-analysis. J Am Geriatr Soc. 2021;69:2973-84
3.
Zurück zum Zitat Van Geel TACM et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99-102 Van Geel TACM et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99-102
4.
Zurück zum Zitat Glüer CC et al. Das Konzept des DVO Frakturrisikorechners. Osteologie. 2023;32:123-32 Glüer CC et al. Das Konzept des DVO Frakturrisikorechners. Osteologie. 2023;32:123-32
5.
Zurück zum Zitat Groenendijk I et al. High versus low dietary protein intake and bone health in older adults: A systematic review and meta-analysis. Comput Struct Biotechnol J. 2019;17:1101-12 Groenendijk I et al. High versus low dietary protein intake and bone health in older adults: A systematic review and meta-analysis. Comput Struct Biotechnol J. 2019;17:1101-12
6.
Zurück zum Zitat Hadji P et al. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: Real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014;25:339-47 Hadji P et al. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: Real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014;25:339-47
7.
Zurück zum Zitat Harvey NC et al. Falls predict fractures independently of FRAX probability: A meta-analysis of the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res. 2018; 33:510-6 Harvey NC et al. Falls predict fractures independently of FRAX probability: A meta-analysis of the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res. 2018; 33:510-6
8.
Zurück zum Zitat Hauff J et al. Single and combined use of fall-risk-increasing drugs and fracture risk: a population-based case-control study. Age Ageing. 2023; 52:afad079 Hauff J et al. Single and combined use of fall-risk-increasing drugs and fracture risk: a population-based case-control study. Age Ageing. 2023; 52:afad079
9.
Zurück zum Zitat Kanis JA et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16:82 Kanis JA et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16:82
10.
Zurück zum Zitat Kendler DL et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230-40 Kendler DL et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230-40
11.
Zurück zum Zitat Khan AA et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom. 2017;20:8-24 Khan AA et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom. 2017;20:8-24
12.
Zurück zum Zitat Larsson BAM et al. The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporos Int. 2021;32:75-84 Larsson BAM et al. The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporos Int. 2021;32:75-84
13.
Zurück zum Zitat Lindsay R et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024-30 Lindsay R et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024-30
14.
Zurück zum Zitat McClung MR et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33:1397-406 McClung MR et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33:1397-406
15.
Zurück zum Zitat Ming Y et al. Medication review in preventing older adults' fall-related injury: A systematic review & meta-analysis. Can Geriatr J. 2021;24:237-50 Ming Y et al. Medication review in preventing older adults' fall-related injury: A systematic review & meta-analysis. Can Geriatr J. 2021;24:237-50
16.
Zurück zum Zitat Deutz NEP et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33:929-36 Deutz NEP et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33:929-36
17.
Zurück zum Zitat Nikolaus T et al. Elderly patients' problems with medication. An in-hospital and follow-up study. Eur J Clin Pharmacol. 1996;49:255-9 Nikolaus T et al. Elderly patients' problems with medication. An in-hospital and follow-up study. Eur J Clin Pharmacol. 1996;49:255-9
18.
Zurück zum Zitat Otto S, Ristow O. Antiresorptiva-assoziierte Kiefernekrosen - ein Update. Der MKG-Chirurg. 2022;15:59-74 Otto S, Ristow O. Antiresorptiva-assoziierte Kiefernekrosen - ein Update. Der MKG-Chirurg. 2022;15:59-74
19.
Zurück zum Zitat Reyes C et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017;28:2997-3004 Reyes C et al. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017;28:2997-3004
20.
Zurück zum Zitat Rupp M et al. Originalarbeit: Inzidenz von Frakturen in der Erwachsenenpopulation in Deutschland. Dtsch Arztebl Int. 2021;118:665-9 Rupp M et al. Originalarbeit: Inzidenz von Frakturen in der Erwachsenenpopulation in Deutschland. Dtsch Arztebl Int. 2021;118:665-9
21.
Zurück zum Zitat Ryg J et al. Hip fracture patients at risk of second hip fracture: A nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res. 2009;24:1299-307 Ryg J et al. Hip fracture patients at risk of second hip fracture: A nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res. 2009;24:1299-307
22.
Zurück zum Zitat Saag KG et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417-27 Saag KG et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417-27
23.
Zurück zum Zitat Van Staa TP et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2005;20:1486-93 Van Staa TP et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2005;20:1486-93
24.
Zurück zum Zitat Tsourdi E et al. Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2021;106:264-81 Tsourdi E et al. Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2021;106:264-81
25.
Zurück zum Zitat Wang Q et al. Effectiveness of exercise intervention on fall-related fractures in older adults: a systematic review and meta-analysis of randomized controlled trials. BMC Geriatr. 2020;20:322 Wang Q et al. Effectiveness of exercise intervention on fall-related fractures in older adults: a systematic review and meta-analysis of randomized controlled trials. BMC Geriatr. 2020;20:322
26.
Zurück zum Zitat Wong RMY et al. The relationship between sarcopenia and fragility fracture - a systematic review. Osteoporos Int. 2019;30:541-53 Wong RMY et al. The relationship between sarcopenia and fragility fracture - a systematic review. Osteoporos Int. 2019;30:541-53
27.
Zurück zum Zitat Wustrack R et al. Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2012;23:53-8 Wustrack R et al. Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2012;23:53-8
Metadaten
Titel
Aspekte bei der Behandlung älterer Patientinnen und Patienten
Die aktuelle Leitlinie für Osteoporose
verfasst von
Univ. Prof. Dr. med. Michael Drey
Univ. Prof. Dr. Dr. Sven Otto
Dr. Friederike Thomasius
Prof. Dr. med. Ralf Schmidmaier
Publikationsdatum
01.11.2024